SouthState Corp’s UroGen Pharma URGN Stock Holding History

SouthState Corp’s Portfolio URGN Stock Details URGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2025 Q2	–	Sell	-56	Closed	-$620	–	1816
2025 Q1	$620	Buy	+56	New	+$597	﹤0.01%	1438

Other funds holding URGN

RTW Investments New York $10B AUM 135.35% 1-Year Est. Return

Toronto Dominion Bank Toronto, Ontario, Ontario, Canada $69.7B AUM 40.86% 1-Year Est. Return

Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

JFG

Jefferies Financial Group New York $14.6B AUM 40.95% 1-Year Est. Return

SCM

Soleus Capital Management Greenwich, Connecticut $2.47B AUM 115.63% 1-Year Est. Return

SCM

Silverarc Capital Management Boston, Massachusetts $980M AUM 470.8% 1-Year Est. Return

ACA

Acorn Capital Advisors New York $352M AUM 299.18% 1-Year Est. Return

MMH

Menora Mivtachim Holdings Ramat Gan, Israel $21.1B AUM 40.03% 1-Year Est. Return

SG Americas Securities New York $92.9B AUM 36.98% 1-Year Est. Return

SouthState Corp's URGN Position: Q2 2025 in Review

SouthState Corp sold out of UroGen Pharma (URGN) in Q2 2025, closing a stake of 56 shares — an estimated $620 sold.

SouthState Corp first reported a position in URGN in Q1 2025 and held it in 1 quarter. The position peaked at $620 in Q1 2025. 150 funds tracked by Wall St. Rank hold URGN as of Q2 2025.

SouthState Corp reported no remaining UroGen Pharma position as of Q2 2025 after selling out during the quarter.
SouthState Corp sold 56 UroGen Pharma shares in Q2 2025, an estimated $620.
SouthState Corp first reported a position in UroGen Pharma in Q1 2025 and held it in 1 quarter.
SouthState Corp's UroGen Pharma position peaked at $620 in Q1 2025.
150 funds tracked by Wall St. Rank held UroGen Pharma as of Q2 2025.

Based on SouthState Corp's 13F filing for Q2 2025, filed 6 Aug 2025.